Wedbush Has Bearish Forecast for Tourmaline Bio Q3 Earnings

Key Points

• Wedbush analysts have lowered their Q3 2025 earnings estimate for Tourmaline Bio to ($0.97) per share, a decrease from their previous estimate of ($0.75).
• The consensus estimate for Tourmaline Bio's full-year earnings is projected at ($3.02) per share, with further earnings also estimated for 2026 and 2027.
• Despite the lowered estimates, multiple analysts such as Guggenheim and Chardan Capital continue to maintain a "buy" rating on the stock, indicating a strong market confidence.

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Wedbush reduced their Q3 2025 earnings per share estimates for Tourmaline Bio in a report issued on Wednesday, August 13th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.97) per share for the quarter, down from their prior estimate of ($0.75). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Tourmaline Bio's Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.77) EPS, Q1 2026 earnings at ($1.10) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.23) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($5.43) EPS, FY2028 earnings at ($6.16) EPS and FY2029 earnings at ($3.87) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.04.

Several other research firms have also recently weighed in on TRML. Guggenheim reaffirmed a "buy" rating and set a $55.00 price objective on shares of Tourmaline Bio in a research report on Thursday, August 14th. Chardan Capital reaffirmed a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a research report on Thursday, August 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Tourmaline Bio currently has a consensus rating of "Buy" and a consensus target price of $50.14.

Tourmaline Bio Trading Up 1.0%

Shares of TRML stock traded up $0.2240 on Monday, hitting $22.6840. 37,981 shares of the stock were exchanged, compared to its average volume of 287,237. The firm has a market capitalization of $582.64 million, a P/E ratio of -6.60 and a beta of 2.04. The business has a 50-day moving average of $19.25 and a 200 day moving average of $16.69. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its position in Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after purchasing an additional 1,232 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Tourmaline Bio by 34.1% in the second quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company's stock valued at $34,000 after buying an additional 535 shares during the period. Virtus ETF Advisers LLC bought a new stake in Tourmaline Bio in the fourth quarter valued at approximately $64,000. Tower Research Capital LLC TRC raised its stake in Tourmaline Bio by 35.7% in the second quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company's stock valued at $51,000 after buying an additional 846 shares during the period. Finally, Brooklyn Investment Group raised its stake in Tourmaline Bio by 148.9% in the first quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock valued at $60,000 after buying an additional 2,347 shares during the period. 91.89% of the stock is owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.